PANCARE FOLOW-UP RECOMMENDATIONS FOR SURVEILLANCE OF LATE EFFECTS

FOLLOW-UP RECOMMENDATIONS FOR SURVEILLANCE OF LATE EFFECTS

Here you can find the PanCare follow-up recommendations for surveillance of late effects.

For survivors: This information is targeted towards HCPs. Please visit the PLAIN summaries for more information on late effects and long-term survivorship care for survivors.

Several evidence-based guidelines incorporating surveillance recommendations for a number of late effects have been developed by the International Guideline Harmonization Group (IGHG) and the PanCare Network, involving healthcare professionals (HCPs), researchers and survivors 1, 2, 3, 4, 5, 6, 7

In addition, consensus-based pragmatic recommendations were developed by PanCareFollowUp for 29 topics relevant to Survivorship Care, but where evidence-based guidelines were not expected to be completed or had not yet been started before the Care intervention cohort study initiation. 8

To develop these consensus-based recommendations, a European expert panel of specialists and survivors involved in PanCareFollowUp, as well as external experts and survivors, was formed. Four existing national long-term follow-up guidelines groups (United Kingdom Children’s Cancer and Leukaemia Group, Dutch Children’s Oncology Group, Scottish Intercollegiate Guidelines Network and the Children’s Oncology Group from North America) were used to identify, extract and compare existing recommendations. Following a robust consultation process involving 19 European countries, 25 consensus-based recommendations were agreed and published. 8

When using these recommendations, it is important to take note of the cross-references that are indicated at certain recommendations. Some measures of surveillance (e.g. weight, height, BMI, blood pressure, fasting glucose or lipid profile) may be performed in primary care in appropriate circumstances.

What is the PanCareFollowUp project?

PanCareFollowUp is an EU-funded project looking at how to best deliver survivorship care to survivors of childhood and adolescent cancer in Europe. The aim of PanCareFollowUp is to deliver care according to recently developed guidelines using an innovative model for person centred care that empowers survivors and supports self-management.

Disclaimer

While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.

It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.

In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.

Contact

If you have any questions about the PanCare Follow-Up Recommendations for Surveillance of Late Effects you can contact info@pancare.eu.

1 Kremer LC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young
adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Pediatr Blood Cancer. 2013;60(4):543-9.

2 Armenian SH, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from
the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123-36.

3 Clemens E, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer
survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration
with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29-e41.

4 Clement SC, et al. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent
and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline
Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018;63:28-39.

5 Mulder RL, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and
young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline
Harmonization Group. Lancet Oncol. 2013;14(13):e621-9.

6 Skinner R, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer
survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration
with the PanCareSurFup Consortium. Lancet Oncol. 2017;18(2):e75-e90.

7 van Dorp W, et al. Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood,
Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline
Harmonization Group in Collaboration With the PanCareSurFup Consortium. J Clin Oncol. 2016;34(28):3440-50.

8 van Kalsbeek RJ, et al. European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. Eur J Cancer. 2021;154:316-328.